The UW Carbone Cancer Center (UWCCC) Drug Discovery Core (DDC) supports world-class biomedical research by facilitating cancer-related pre-clinical drug discovery through the integration of high throughput screening, medicinal chemistry and pharmacology. These services are provided through the partnership of the Small Molecule Screening Facility and the Medicinal Chemistry Center in the School of Pharmacy.
The DDC Small Molecule Screening provides libraries of more than 400,000 compounds, robotic liquid handling and plate readers for high throughput screening of cell-based and biochemical assays in 96 to 1536-well plate formats. Computational resources and expertise are provided for in silico screens of millions of chemicals and for molecular modeling. Other specialized equipment includes a Seahorse Bioanalyzer for evaluation of cellular metabolism in 96-well format.
The DDC Medicinal Chemistry provides synthesis of small molecules that have been identified as bioactive, development of lead and probe molecules for target identification, hit-to-lead optimization to improve drug-like properties, construction of libraries of small molecules, and large-scale preparative synthesis to support animal model studies. Evaluation of in vitro and in vivo pharmacology is provided through in-house assays and contracts maintained with external contract research organizations.
Learn more about the Drug Discovery Core's Scientific Accomplishments.
Any published research which received funding from the UWCCC Cancer Center Support Grant (CCSG), including the use of UWCCC Shared Resources to generate or analyze data or conduct clinical trials, must reference the UWCCC.
DDC Small Molecule Screening
DDC Medicinal Chemistry
Hours: 9am-5pm M-F